140 related articles for article (PubMed ID: 15274700)
1. Topical immunomodulation in dermatology: potential of toll-like receptor agonists.
Hengge UR; Ruzicka T
Dermatol Surg; 2004 Aug; 30(8):1101-12. PubMed ID: 15274700
[TBL] [Abstract][Full Text] [Related]
2. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum.
Hengge UR; Cusini M
Br J Dermatol; 2003 Nov; 149 Suppl 66():15-9. PubMed ID: 14616340
[TBL] [Abstract][Full Text] [Related]
3. [Topical immunomodulators in dermatology].
Meykadeh N; Hengge UR
Hautarzt; 2003 Jul; 54(7):641-61; quiz 662. PubMed ID: 12908453
[TBL] [Abstract][Full Text] [Related]
4. Topical immunomodulators--progress towards treating inflammation, infection, and cancer.
Hengge UR; Benninghoff B; Ruzicka T; Goos M
Lancet Infect Dis; 2001 Oct; 1(3):189-98. PubMed ID: 11871495
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod: a cytokine inducer.
Dahl MV
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S205-8. PubMed ID: 12271278
[No Abstract] [Full Text] [Related]
6. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.
Stanley MA
Clin Exp Dermatol; 2002 Oct; 27(7):571-7. PubMed ID: 12464152
[TBL] [Abstract][Full Text] [Related]
8. Role of topical therapies in the management of cutaneous disease.
Skinner R
J Cutan Med Surg; 2004; 8 Suppl 3():22-31. PubMed ID: 15647859
[TBL] [Abstract][Full Text] [Related]
9. New insights into imiquimod's mechanisms of action.
Martín-García RF
J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157
[TBL] [Abstract][Full Text] [Related]
10. Topical immunotherapy: what's new.
Sauder DN; Mofid MZ
Dermatol Clin; 2005 Apr; 23(2):245-58. PubMed ID: 15837154
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.
Sauder DN
J Cutan Med Surg; 2004; 8 Suppl 3():3-12. PubMed ID: 15647861
[TBL] [Abstract][Full Text] [Related]
12. The treatment of viral infections and nonmelanoma skin cancers.
Del Rosso JQ
Cutis; 2007 Apr; 79(4 Suppl):29-35. PubMed ID: 17508493
[TBL] [Abstract][Full Text] [Related]
13. Imiquimod; an international update on therapeutic uses in dermatology.
Tyring S; Conant M; Marini M; Van Der Meijden W; Washenik K
Int J Dermatol; 2002 Nov; 41(11):810-6. PubMed ID: 12453012
[TBL] [Abstract][Full Text] [Related]
14. Topical imiquimod treatment of human papillomavirus in a patient with human immunodeficiency virus.
Gilbert J; Drehs MM; Weinberg JM
Acta Derm Venereol; 2001; 81(4):301-2. PubMed ID: 11720183
[No Abstract] [Full Text] [Related]
15. Imiquimod: modes of action.
Bilu D; Sauder DN
Br J Dermatol; 2003 Nov; 149 Suppl 66():5-8. PubMed ID: 14616337
[No Abstract] [Full Text] [Related]
16. The role of topical immune response modifiers in skin cancer.
Woodmansee C; Pillow J; Skinner RB
Drugs; 2006; 66(13):1657-64. PubMed ID: 16978032
[TBL] [Abstract][Full Text] [Related]
17. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
Stockfleth E; Trefzer U; Garcia-Bartels C; Wegner T; Schmook T; Sterry W
Br J Dermatol; 2003 Nov; 149 Suppl 66():53-6. PubMed ID: 14616352
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
Gilliet M; Conrad C; Geiges M; Cozzio A; Thürlimann W; Burg G; Nestle FO; Dummer R
Arch Dermatol; 2004 Dec; 140(12):1490-5. PubMed ID: 15611427
[TBL] [Abstract][Full Text] [Related]
19. Bowenoid papulosis successfully treated with imiquimod 5% cream.
Shimizu A; Kato M; Ishikawa O
J Dermatol; 2014 Jun; 41(6):545-6. PubMed ID: 24909216
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
